News & Trends - MedTech & Diagnostics
3D printed limb to be the more cost-effective future of prosthetics
A new 3D printed prosthetic hand that could make prosthetics both light and affordable has been designed by Australian researchers at the University of Melbourne.
The team developed a prosthetic hand called ‘X-limb’ which is capable of three grasp types including a pinch, tripod, and power grasp, allowing the user to perform tasks such as grasping a mobile phone, tying a shoelace, zipping a jacket, or using scissors.
The hands weigh only 253 grams and are operated by sensors placed on the surface of the skin, or by buttons located on the wrist.
They are expected to last for at least 12 months and cost as little as $200USD in materials to produce.
Register FREE & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.
In alignment with the Federal Government’s mental health initiative the #SelfcareInHealthcare campaign has been launched to encourage Pharma, Biotech and MedTech industry professionals to take action on mental health during COVID-19. LinkedIn post.
News & Trends - Pharmaceuticals
Heart Week: Uniting patient and cardiologist voices in shaping a new future for patient outcomes
Coinciding with the start of the Heart Week (9 – 12 May), Professor Gemma Figtree, Interventional Cardiologist and Immediate Past […]
MoreNews & Trends - MedTech & Diagnostics
‘It’s a marathon not a sprint’: Industry leaders chart next steps in medtech’s sustainability journey
Ahead of World Environment Day in June, Jane Crowe, Managing Director of Cardinal Health Australia and New Zealand and Pravin […]
MoreNews & Trends - Pharmaceuticals
Vaccination accounts for almost half of mortality decline in infants
Pharma News: Researchers have mapped the impact of vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation […]
MoreNews & Trends - Pharmaceuticals
AbbVie, Pfizer and Bayer therapies to be considered at upcoming PBAC intracycle meeting
Pharma News: Therapies from AbbVie, Pfizer and Bayer are due to be considered at the Pharmaceutical Benefits Advisory Committee (PBAC) […]
More